Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

被引：0
|
作者：
Steven B. Zeliadt
David F. Penson
机构：
[1] Fred Hutchinson Cancer Research Center,Division of Public Health Sciences
[2] Keck School of Medicine,Departments of Urology and Preventive Medicine
[3] University of Southern California,undefined
[4] Departments of Urology,undefined
来源：
PharmacoEconomics | 2007年 / 25卷
关键词：
Prostate Cancer; Androgen Deprivation Therapy; Flutamide; Advanced Prostate Cancer; Goserelin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease. We identified 58 articles addressing economic issues related to metastatic prostate cancer.
引用
收藏
页码：309 / 327
页数：18
相关论文
共 50 条
  • [41] Treatment options for early prostate cancer
    Kirby, R
    UROLOGY, 1998, 52 (06) : 948 - 962
  • [42] New treatment options in metastatic breast cancer
    Johnston, S. R. D.
    CANCER RESEARCH, 2013, 73
  • [43] Improving treatment options for metastatic colorectal cancer
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 619 - 619
  • [44] Expanding treatment options for metastatic gastric cancer
    Roviello, Giandomenico
    Borsella, Giulia
    Generali, Daniele
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S22 - S24
  • [45] Treatment options for chemotherapy in metastatic gastric cancer
    Wagner, A. D.
    Stahl, M.
    ONKOLOGE, 2008, 14 (04): : 381 - +
  • [46] New Treatment Options in Metastatic Pancreatic Cancer
    Fudalej, Marta
    Kwasniewska, Daria
    Nurzynski, Pawel
    Badowska-Kozakiewicz, Anna
    Mekal, Dominika
    Czerw, Aleksandra
    Sygit, Katarzyna
    Deptala, Andrzej
    CANCERS, 2023, 15 (08)
  • [47] Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data
    Baston, Catalin
    Preda, Adrian
    Guler-Margaritis, Silviu S.
    Sinescu, Ioanel
    Gingu, Constantin
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 576 - 583
  • [48] Metastatic castration-resistant prostate cancer-what are rational sequential treatment options?
    Horak, Jana
    Petrausch, Ulf
    Omlin, Aurelius
    UROLOGIE, 2023, : 1295 - 1301
  • [49] Treatment options in hormone-refractory metastatic prostate carcinoma
    Fusi, A
    Procopio, G
    Della Torre, S
    Ricotta, R
    Bianchini, G
    Salvioni, R
    Ferrari, L
    Martinetti, A
    Savelli, G
    Villa, S
    Bajetta, E
    TUMORI JOURNAL, 2004, 90 (06): : 535 - 546
  • [50] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
12345